Abcam Plc (ABC) Insider Buys £10,532.16 in Stock

Abcam Plc (LON:ABC) insider Suzanne Smith purchased 864 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was acquired at an average price of GBX 1,219 ($15.93) per share, for a total transaction of £10,532.16 ($13,762.13).

ABC opened at GBX 1,229 ($16.06) on Friday. Abcam Plc has a one year low of GBX 9.73 ($0.13) and a one year high of GBX 1,290 ($16.86).

The company also recently announced a dividend, which will be paid on Friday, November 30th. Stockholders of record on Thursday, November 8th will be given a dividend of GBX 8.58 ($0.11) per share. The ex-dividend date is Thursday, November 8th. This represents a dividend yield of 0.65%. This is a boost from Abcam’s previous dividend of $3.42.

ABC has been the topic of a number of research analyst reports. Berenberg Bank upgraded Abcam to a “buy” rating and lifted their target price for the stock from GBX 1,230 ($16.07) to GBX 1,640 ($21.43) in a research report on Tuesday, July 31st. Peel Hunt reiterated a “hold” rating on shares of Abcam in a research report on Thursday, November 1st. Finally, Numis Securities reiterated a “hold” rating on shares of Abcam in a research report on Tuesday, September 11th.

COPYRIGHT VIOLATION WARNING: “Abcam Plc (ABC) Insider Buys £10,532.16 in Stock” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at

About Abcam

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Featured Article: Initial Public Offering (IPO)

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with's FREE daily email newsletter.

Leave a Reply